US 12,247,078 B2
ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
Mark Throsby, Utrecht (NL); Cecilia Anna Wilhelmina Geuijen, Utrecht (NL); David Andre Baptiste Maussang-Detaille, Utrecht (NL); and Ton Logtenberg, Utrecht (NL)
Assigned to Merus N.V., Utrecht (NL)
Filed by Merus N.V., Utrecht (NL)
Filed on Feb. 21, 2024, as Appl. No. 18/583,481.
Application 18/449,460 is a division of application No. 16/499,185, granted, now 11,780,925, issued on Oct. 10, 2023, previously published as PCT/NL2018/050206, filed on Apr. 3, 2018.
Application 18/583,481 is a continuation of application No. 18/449,460, filed on Aug. 14, 2023.
Claims priority of application No. 17164292 (EP), filed on Mar. 31, 2017.
Prior Publication US 2024/0182587 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2863 (2013.01) [C07K 16/468 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01)] 20 Claims
 
1. A method of treating non-small cell lung cancer or pancreatic cancer in a subject, wherein the method comprises administering to the subject a bispecific antibody that comprises a first antigen-binding site that can bind an extracellular part of ErbB-2, and a second antigen-binding site that can bind an extracellular part of ErbB-3, wherein cells of said cancer comprise an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location;
the first antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:40, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 41, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:42; and
the second antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:54, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:56; and
wherein the first antigen binding site and the second antigen binding site comprise a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:75, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a light chain CDR3 comprising the amino acid sequence SEQ ID NO:77.